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Functional Link between the Mammalian
Exosome and mRNA Decapping
m7GDP. This activity preferentially hydrolyzes methyl-
ated cap and requires an RNA longer than 25 nucleotides
(LaGrandeur and Parker, 1998). Auxiliary factors that
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604 Allison Road augment the function of Dcp1p have also been identified
(Bonnerot et al., 2000; Bouveret et al., 2000; DunckleyPiscataway, New Jersey 08854
and Parker, 1999; Zhang et al., 1999a). Recently, a puta-
tive mammalian activity functionally equivalent to the
yeast Dcp1p was identified (Gao et al., 2001). A mamma-Summary
lian decapping activity that functions on capped oligo-
nucleotides that are shorter than 10 nucleotides in lengthMechanistic understanding of mammalian mRNA turn-
over remains incomplete. We demonstrate that the has also been reported and proposed to clear exoribo-
nucleolytic products that retain a cap structure (Nuss3 to 5 exoribonuclease decay pathway is a major
contributor to mRNA decay both in cells and in cell et al., 1975).
The pathway of mRNA turnover is also best studiedextract. An exoribonuclease-dependent scavenger
decapping activity was identified that follows decay in yeast and predominantly involves removal of the
poly(A) tail followed by decapping (Decker and Parker,of the mRNA and hydrolyzes the residual cap. The
decapping activity is associated with a subset of the 1993; Muhlrad et al., 1994). The poly(A) tail is initially
deadenylated to an oligo(A), which renders the mRNAexosome proteins in vivo, implying a higher-order deg-
radation complex consisting of exoribonucleases and susceptible to decapping by Dcp1p (Beelman et al.,
1996). The exposed 5 end is subsequently degradeda decapping activity, which together coordinate the
decay of an mRNA. These findings indicate that follow- by Xrn1, a 5 to 3 exoribonuclease (Hsu and Stevens,
1993). An alternative pathway also exists where a com-ing deadenylation of mammal mRNA, degradation pro-
ceeds by a coupled 3 to 5 exoribonucleolytic activity plex of proteins (termed the exosome) degrade the
mRNA in a 3 to 5 direction following deadenylationand subsequent hydrolysis of the cap structure by a
scavenger decapping activity. (Anderson and Parker, 1998; Mitchell et al., 1997). The
exosome also plays a significant role in a nuclear discard
pathway to clear unspliced pre-mRNA in yeast (Bous-Introduction
quet-Antonelli et al., 2000).
We have developed an in vitro mRNA decay assayAll eukaryotic mRNAs are modified at the 5 end with
the addition of a cap structure. In nearly all cases the that recapitulates regulated mRNA turnover including
PABP-dependent deadenylation (Wang et al., 1999;cap consists of a guanine nucleoside methylated at the
N-7 position (m7G) covalently attached to the terminal Wang and Kiledjian, 2000b). Using this system, we now
present evidence that mammalian mRNA turnover cannucleoside of the RNA with an unusual 5-5 linkage
(Shatkin, 1976). The 3 ends of most mRNA are also proceed through a coupled 3 to 5 exonuclease degra-
dation-dependent decapping pathway.modified and contain a stretch of adenosine residues
(Sachs, 1993). Both of these structures serve to protect
the respective ends of the mRNA from exoribonucleo- Results
lytic degradation (Ross, 1995), are involved in transport
of the mRNA to the cytoplasm (Izaurralde et al., 1995; Capped and Polyadenylated RNA Is More Stable
Jarmolowski et al., 1994; Wickens and Gurdon, 1983), than Uncapped and Polyadenylated RNA In Vitro
and contribute to translation of the mRNA (Gingras et We recently reported an in vitro mRNA decay system
al., 1999; Hentze, 1997; Sachs et al., 1997). A role for that recapitulated regulated mRNA turnover by using
the cap has also been demonstrated in the splicing of the  globin transcript as a model system. Consistent
pre-mRNA (Konarska et al., 1984). The 5 cap is bound with previous demonstrations of mRNA turnover in cells,
by a cap binding heterodimeric complex consisting of the initial step for the degradation of RNA in this system
CBC20 and CBC80 in the nucleus (Izaurralde et al., 1994) is the removal of the poly(A) tail (Wang et al., 1999). We
and by the cytoplasmic cap binding protein eIF4E in the now address more general mechanistic questions of
cytoplasm (Gingras et al., 1999). mRNA turnover in mammals. We first asked whether
The protein components and the mechanism of m7G the in vitro system recapitulates the differential stability
cap addition have been extensively characterized in many observed in cells between capped and uncapped mRNA
species (Furuichi and Shatkin, 2000). In contrast, much (Drummond et al., 1985; Furuichi et al., 1977; Green et
less is known about the mechanism involving removal al., 1983; Krieg and Melton, 1984). We used the pcDNA3
of the cap. Much of our understanding of decapping polylinker (pcP) region as a generic RNA substrate and
comes from work in the yeast Saccharomyces cerevis- carried out the reactions in human erythroleukemia K562
iae where the gene encoding the decapping enzyme cytosolic S130 extract. The RNA was transcribed, with
Dcp1p has been cloned (Beelman et al., 1996). Dcp1p is or without cap analog, in the presence of [-32P]UTP
a pyrophosphatase that decaps the mRNA by releasing from a template that introduced 60 adenosine residues
at the 3 end. As shown in Figure 1A, capped RNA was
more stable, with a half-life greater than the 2 hr reaction1 Correspondence: kiledjia@biology.rutgers.edu
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Figure 1. 3 to 5 RNA Degradation Is More Prominent than 5 to 3 Degradation In Vitro
(A) Uniformly labeled capped and uncapped polyadenylated pcP RNA were used in an in vitro decay assay with K562 S130 extract for the
indicated times, and the RNA products were resolved on a denaturing 7 M urea/8% polyacrylamide gel and visualized by autoradiography.
Migration of the unadenylated pcP RNA (A) and migration of an internal control oligonucleotide, which was included in the stop buffer to
enable quantitation, are indicated on the left. The DNA size markers are shown on the right in nucleotides. The RNA substrate is schematically
denoted beneath each panel, and the asterisks represent the position of the 32P labeling. The RNA cap is represented by a circle. The line
depicts the RNA, and the extent of polyadenylation is denoted by the “A” with the number of nucleotides shown as a subscript.
(B) In vitro decay reactions with capped or uncapped pcP RNAs containing a G16 track on the 3 end were carried out in K562 S130 extract.
(C) In vitro decay reactions with capped or uncapped unadenylated pcP RNAs were carried out in K562 S130 extract.
(D) The data presented in (B) and (C) are plotted from three independent experiments with the corresponding error bars. The RNAs are
depicted schematically on the right. Quantitation from (A) using polyadenylated RNA were not included in the graph since they are similar to
results obtained for RNA containing a G16 track (B).
(E) Capped and uncapped pcP RNA containing an internal G16 track at position 96 were used in an in vitro decay reaction with K562 S130
extract. The RNA and the band corresponding to the blocked intermediate from the 3 end is schematically depicted on the bottom (112
nucleotides) and denoted by an arrow on the left.
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time, while the half-life of the uncapped RNA was ap- also observed with uncapped RNA (lanes 6–8), further
supporting the significant role of 3 to 5 exoribo-proximately 60 min. The differential stability of the two
RNAs that differ only by the presence or absence of the nucleases. Upon overexposure of the gel, a minor band
in the 56 nucleotide range corresponding to a 5 end5 cap suggests that a 5 to 3 exoribonuclease activity
contributes to the turnover observed in these reactions. block can be detected with the uncapped RNA consis-
tent with the minor contribution for this activity.Furthermore, both RNAs degraded through a deadenyl-
ation process, as indicated by the presence of the
phased poly(A) plus intermediate which we have pre- 3 to 5 Exoribonucleases Are Major Contributors
viously shown is due to sequential removal of PABP and to mRNA Decay in Mammalian Cells
rapid decay of the RNA upon removal of the terminal To determine whether 3 to 5 exoribonucleases are ma-
PABP (Wang et al., 1999). jor contributors in intact cells, we introduced a similar
The presence of a 5 to 3 exoribonuclease activity set of [32P]RNAs into K562 cells and followed their fate
was tested by placing a G track on the 3 end of the over time. A set of six RNAs were electroporated into
RNA to inhibit 3 to 5 exoribonuclease activity. Poly(G) cells as described in Experimental Procedures. The
stretches have been shown to efficiently block exoribo- RNAs either contained or lacked an m7G cap at the 5
nucleases in yeast (Muhlrad et al., 1994). Capped and end and either lacked or contained a poly(A) tail or a
uncapped pcP RNAs containing 16 guanosine nucleo- G16 track at the 3 end. Cells were harvested at various
tides (G16) at their 3 end were generated (pcP-G16). As times up to 6 hr postelectroporation, and the RNA were
can be seen in Figure 1B and presented in graph form resolved and visualized. Similar to the results observed
in Figure 1D, both RNAs are relatively stable when the in the in vitro decay system, RNAs containing a block
3 end is protected. However, the differential stability on the 3 end were more stable than RNAs containing
between the capped and uncapped RNAs, which was a block on the 5 end (Figure 2). The half-life of the RNA
observed with the polyadenylated RNAs, is maintained. protected at the 5 end with a cap but lacking a block
Similar results were also obtained by placing a stable on the 3 end is approximately 60 min (Figures 2A and
stem loop structure at the 3 end or by using polyadenyl- 2D). The half-life of an RNA lacking a cap and protected
ated RNAs in an extract depleted for the deadenylating with a G16 track on the 3 end is over 3-fold higher (Fig-
nuclease PARN (data not shown). The half-life of the ures 2B and 2D), while a polyadenylated RNA is more
capped RNA with a G16 track is greater than the 2 hr than 4-fold more stable (Figure 2C). These data support
time course of the experiment, while the half-life of the the conclusion that degradation from the 3 end of an
uncapped RNA with a G16 is 90 min (Figure 1D). These mRNA is a major decay pathway in cells as well. Also
results are consistent with the presence of 5 to 3 exori- similar to the in vitro results, polyadenylated RNAs appear
bonucleases in mammalian cells. to undergo deadenylation as the first step in the decay
process, and the deadenylation was indistinguishable re-
gardless of the presence or absence of the 5 cap.3 to 5 Exoribonuclease Activity Is a Major
Contributor to RNA Decay in Mammalian Extract The above experiments were carried out with RNA
introduced into cells. We were also interested in de-The relative contribution of the different exoribo-
nuclease activities to RNA degradation was next ad- termining whether an endogenous mRNA undergoes a
predominant 3 to 5 decay. To assess the decay path-dressed. The relative stability of capped and uncapped
RNAs lacking a poly(A) tail is presented in Figure 1C. way of an endogenous mRNA, we arbitrarily chose c-myc,
a relatively short-lived mRNA, to enable detection ofBoth RNAs were equally unstable, with half-lives of less
than 20 min. Similar results were also observed with decay products within a manageable experimental time
frame. RNA was isolated from K562 cells at various timeslonger RNAs (data not shown). Quantitations of the re-
sults presented in Figures 1B and 1C using capped or following Actinomycin D treatment and was analyzed
by RNase protection assays (RPA) using two differentuncapped RNAs containing or lacking a G16 track block
at the 3 end are plotted in Figure 1D. Quantitations for probes. One probe was complementary to the 5 end
of the mRNA, and the second was complementary tothe polyadenylated RNAs (Figure 1A) were indistinguish-
able from the G16-containing RNA and were omitted from the 3 end. We reasoned that RPA might be sensitive
enough to detect the rare intermediates that are in thethe graph. A comparison of the half-life for the 5 end
protected capped pcP RNA to that of the 3 end pro- process of being degraded from one end or the other
despite the rapid action of exoribonucleases. If the RNAstected uncapped pcP-G16 RNA, indicated a 5-fold
greater contribution to the degradation of the RNA from were degraded predominantly from the 3 end, the rela-
tive ratio of mRNAs containing the 3 end would be lessthe 3 end. These results suggest that the 3 to 5 exori-
bonuclease activity is the major contributor to RNA deg- than that containing the 5 end. The opposite would be
true if the decay occurred from the 5 end. Cytoplasmicradation in mammalian extract.
To further substantiate the directionality of the degra- RNA was used in the analysis to eliminate potential com-
plications of trapped transcription intermediates upondation in extract, the G16 track was inserted internally
within the RNA at nucleotide 96. A block of 5 to 3 transcription arrest. As shown in Figure 2E (lanes 6–10
and graph), the relative ratio of mRNAs containing andegradation would generate a 56 nucleotide intermedi-
ate, while a block of decay from the 3 end would gener- intact 3 end relative to an intact 5 end decreased over
time, indicating that the mRNA is predominantly de-ate a 112 nucleotide intermediate. As shown in Figure
1E, the 112 nucleotide band accumulates over time graded from the 3 end. Similar results were also de-
tected using HeLa cells (Figure 2E, lanes 11–15). Thesewhen capped RNA is used, corresponding to a block of
3 to 5exoribonucleases (lanes 2–4). A similar result was results are consistent with the directionality of c-myc
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Figure 2. 3 to 5 Degradation of RNAs in Cells
Capped and uncapped 32P uniformly labeled pcP RNAs containing or lacking a block on the 3 end were introduced into cells, and the half-
lives were determined. Uniformly labeled capped and uncapped pcP RNAs were transfected into K562 cells, and the RNA products were
isolated at the indicated times and resolved as described in the legend to Figure 1.
(A) RNAs lacking a structure on the 3 end.
(B) RNAs containing a G16 track on the 3 end.
(C) RNAs containing a poly(A) tail at the 3 end.
(D) The data presented in (A) and (B) are plotted. The numbers were derived from three independent experiments, and error bars are shown.
(E) RPA to detect the presence of the 5 end (nucleotides 249–350) and the 3 end (nucleotides 1829–2032) of the c-myc mRNA were carried
out with cytoplasmic RNA from K562 cells (lanes 6–10) or HeLa cells (lanes 11–15) following the indicated times of Actinomycin D treatment.
The bands corresponding to the 5 fragment or the 3 fragment are indicated on the left, and the location of the probes relative to the translation
start site (AUG) and stop codon (UAA) are shown schematically on the bottom. Quantitations from three independent experiments were plotted
as a percent of the 3 fragment to the 5 fragment. The ratio at time zero was set to 100%.
mRNA decay reported in vitro (Brewer, 1998). Collec- The Presence of a Degradation-Dependent
Decapping Activity in Human Cellstively, our data demonstrates that, with both RNA intro-
duced into cells and endogenous mRNA, the primary RNA decapping activity has been demonstrated in the
yeast Saccharomyces cerevisiae. Dcp1p can hydrolyzedirection of decay is from the 3 end of the mRNA.
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Figure 3. Detection of a Methyl Cap-Specific Decapping Activity in Mammalian S130 Extract
Unadenylated and cap-labeled pcP RNA was used in decay assays to detect decapping activity in S130 extract.
(A) In vitro decay assays were carried out by incubating cap-labeled (m7G*pppG-) pcP RNA with K562 (lanes 2–5) or HeLa (lane 6) S130 extract
at 37C for the indicated times. Reaction products were resolved on PEI TLC plates. Standards were developed on the TLC simultaneously
and visualized by ultraviolet shadowing, and their migration is indicated on the left. The percent of input RNA that was decapped (where the
sum of both decapping products was used) is indicated. The RNA used in the reaction is schematically depicted on the bottom where the
cap is represented by the m7GpppG and the asterisk denotes the labeled phosphate.
(B) An in vitro decay assay was carried out with 5 cap-labeled pcP RNA in K562 S130 extract. The products from lane 2 were treated with
either nucleoside diphosphate kinase (NDPK; lane 3) or calf intestinal phosphatase (lane 7). A decay reaction carried out with extract containing
a phosphatase inhibitor cocktail is shown in lane 6. The Dcp1p decapping product is shown in lane 4, and its treatment with NDPK is presented
in lane 5. Inorganic phosphate (32Pi) is shown in lane 8. Migration of the cold standards are indicated on the left, and a schematic of the pcP
RNA is shown on the bottom.
(C) In vitro decay assays using unadenylated, cap-labeled pcP RNA (shown on the bottom) were carried out for 30 min at 37C in K562 S130
extract (lane 2) with the indicated amount of m7GpppG cap analog (lanes 3 and 4) or unmethylated GpppG cap analog (lanes 5 and 6).
Resolution of nuclease P1-treated substrate RNA is shown in lane 7. Nuclease P1 degrades the phosphodiester bonds within the body of the
RNA to release the cap (m7GpppG).
the m7G cap structure on the 5 end of an mRNA to the lower spot accumulated with longer incubation
times. By 1 hr, 75% of the input RNA was decapped. Arelease m7GDP (Beelman et al., 1996). A decapping ac-
tivity has also been reported in mammalian cells, but similar activity was also detected in HeLa cells (lane 6).
These data demonstrate that a decapping pyrophos-this activity releases m7GMP (Nuss et al., 1975). We were
interested in determining whether a decapping activity phatase activity exists in mammalian cells.
Using enzymatic assays, we demonstrated that thewas present in the in vitro decay system and how such
an activity would coincide with the above observation primary cleavage product is m7GMP and that the lower
spot is inorganic phosphate hydrolyzed from thethat 3 to 5 degradation was the prominent decay activ-
ity. The pcP RNA, which is 136 nucleotides long, was used m7GMP. An aliquot of the products generated from a 30
min in vitro decay assay (Figure 3B, lane 2) was treatedas a substrate. The RNA was capped with [-32P]GTP
using the vaccinia capping enzyme, which labels the cap with nucleotide diphosphate kinase (NDPK) (lane 3). NDPK
converts GDP to GTP but does not use GMP as a sub-at the first phosphate following the methylated guano-
sine (m7G*pppG; see Experimental Procedures). The strate. NDPK treatment had no effect on the accumulation
of either spot (compare lane 2 to lane 3), indicating thatRNA was used in an in vitro decay assay as above.
A time course in vitro decay reaction was carried out the lower spot was not m7GDP. As expected, the m7GDP
product produced by yeast Dcp1p (lane 4) was con-with cap-labeled unadenylated pcP RNA for up to one
hour in cytoplasmic K562 S130 extract. The potential verted to m7GTP by NDPK (lane 5). When the decay
reactions were carried out in the presence of phospha-pyrophosphatase decapping products were resolved by
polyethyleneimine (PEI)-cellulose thin-layer chromatog- tase inhibitors, the m7GMP product was enriched (lane
6). Conversely, when the reaction products from laneraphy (TLC) (Beelman et al., 1996; Zhang et al., 1999b).
Two spots were detected (Figure 3A; lanes 2–5). The 2 were treated with a phosphatase, the lower spot was
enriched (lane 7). These data suggest that the slower mi-top spot comigrated with the m7GMP standard, while
the second spot comigrated with the m7GDP standard grating band is inorganic phosphate (32Pi) released from
the m7GMP product by a phosphatase in the extract.as well as inorganic phosphate (see below). The m7GMP
was the predominant product at the earlier time, while Consistent with this conclusion, 32Pi comigrates with the
Cell
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Figure 4. The DcpS Decapping Activity Is Dependent on 3 to 5 Degradation
(A) Cap-labeled RNAs lacking (lanes 1–5) or containing (lanes 6–10) a G16 track were used in an in vitro decay assay for the indicated times,
and the products were resolved by TLC. Labeling is as described in the legend to Figure 3.
(B) Cap-labeled RNAs lacking (lanes 1–4) or containing (lanes 5–8) a poly(A) tail were used in an in vitro decay assay for the indicated times,
and the products were resolved by TLC.
(C) Cap-labeled and polyadenylated (lanes 1–5) or unadenylated RNAs (lanes 6–10) were used in an in vitro decay assay for 10 min with K562
S130 extract or extract depleted of PABP (PABP), as marked. Recombinant PABP (15 pmol; lanes 4 and 9) or the RNA binding domain of
hnRNP U (lanes 5 and 10) were added as indicated.
lower spot as well as the m7GDP standard (lane 8). These petitor inhibits the subsequent decapping step, re-
sulting in the accumulation of the exoribonucleasedata demonstrate the following: first, that m7GMP is the
primary cleavage product of the decapping activity, and byproduct.
second, that the product comigrating with the m7GDP
standard is not m7GDP but instead is inorganic 32Pi hy-
drolyzed from the original m7GMP. We conclude that a Dependence of the Decapping Activity on 3 to 5
Exoribonucleolytic Decaypyrophosphatase activity is present in mammalian cells,
which hydrolyzes the cap and releases m7GMP. We reasoned that if the decapping occurred following
3 to 5 degradation of the RNA, placement of the G track
at the 3 end to block exoribonuclease activity shouldThe Decapping Activity Is Specific
to the Methylated Cap Structure inhibit decapping. Cap-labeled pcP and pcP-G16 RNAs
were utilized in a time course in vitro decay reaction,The cap structure of all eukaryotic cellular mRNA con-
tains a methyl group at the N-7 position of the terminal and the products were resolved by TLC. As expected,
the pcP RNA was efficiently decapped with 72% of theguanosine. The specificity of the pyrophosphatase ac-
tivity for methylated cap was determined by a competi- RNA decapped at the 1 hr time point (Figure 4A, lanes
1–5). However, the presence of the G16 track on the RNAtion assay using methylated cap analog (m7GpppG) or
unmethylated cap analog (GpppG). As expected, addi- efficiently inhibited decapping, with 10% decapping de-
tected at the final time point (lanes 6–10). A direct corre-tion of m7GpppG competed for the decapping activity
and reduced the accumulation of m7GMP (Figure 3C, lation between the extent of RNA degradation and the
accumulation of the decapping products was observedlanes 3 and 4). Competition with GpppG had no effect
(lanes 5 and 6), demonstrating a requirement for the N-7 by using uniformly labeled RNA in an identical reaction
(data not shown, similar to Figure 1B). Similarly, themethyl group in the decapping specificity. Consistent
with the methyl-specificity, capped RNA lacking the N-7 presence of a poly(A) tail on the 3 end also inhibited
decapping (Figure 4B). Unadenylated RNA was consis-methyl group was not decapped by this activity (data
not shown). Surprisingly, in addition to inhibiting the tently decapped at a rate at least 5-fold greater than
that of polyadenylated RNA (compare lanes 2–4 withm7GMP product formation, the m7GpppG competitor
stimulated a new product (lanes 3 and 4), which comi- 6–8). As expected, reactions carried out with PABP-
depleted extract, which facilitates deadenylation andgrates with cold m7GpppG standard and the m7GpppG
cap structure released by Nuclease P1 treatment of the subsequent degradation of the RNA (Wang et al., 1999;
Wang and Kiledjian, 2000b), also resulted in a correspond-capped-labeled RNA (lane 7). We conclude the new spot
is m7GpppG. Accumulation of the m7GpppG cap product ing greater decapping activity (Figure 4C, lane 3); this
was reversed upon the stabilization of the RNA with thein lanes 3 and 4 indicates that the exoribonuclease activ-
ity precedes decapping. Therefore, the RNA is initially addition of recombinant PABP (lane 4). We conclude
that the decapping activity that releases m7GMP func-degraded by a 3 to 5 exoribonuclease and subse-
quently decapped. Addition of the m7GpppG cap com- tions on degraded RNA and is a scavenger activity that
Mammalian Degradation-Dependent Decapping
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peak of DcpS activity was exclusively detected in the
300 kDa range. Since DcpS only functions on short
capped oligonucleotides (Figure 3), these results sug-
gest that exoribonuclease(s) and DcpS could both be
associated within the same large complex.
An association between the DcpS and exosome pro-
teins was next tested. The exosome complex was immu-
nopurified with antibodies to two of the human exosome
components, hRrp40p and hRrp41p (Ski6p) (Brouwer et
al., 2001), as described in Experimental Procedures. 32P-
labeled cap analog was incubated with the immunopuri-
fied complex immobilized on the beads, and the reaction
products were resolved by TLC. The cap analog was
efficiently hydrolyzed to m7GMP when using the com-
plexes purified with antisera specific to hRrp40p and
hRrp41p but not their respective preimmune sera (Figure
6B; compare lane 2 to lane 6 and lane 4 to lane 7).
Figure 5. The Presence of DcpS in Yeast The interaction was also detected when using RNase-
Total yeast extract from wild-type (lanes 2–4), dcp1 (lanes 5–7), and treated extract to preclude RNA tethering (lanes 3 and
dcp2 (lanes 8–10) strains were incubated with 32P-labeled cap analog
5). Collectively, the association of DcpS with hRrp40pin standard in vitro decay conditions for 15 min, and the decapping
and hRrp41p in conjunction with the 300 kDa size of thisproducts were detected by TLC. Added was 100 M of methylated
complex implies that DcpS associates with a subset of(m7GpppG) or unmethylated (GpppG) cap competitor, as shown.
exosome proteins that includes hRrp40p and hRrp41p.
ultimately hydrolyzes the cap structure. We will refer to Discussion
this activity as decapping scavenger (DcpS) activity.
The above data indicate that DcpS functions on mRNAs We present three findings pertaining to mammalian
that have been degraded in the 3 to 5 direction. Since mRNA turnover in this report: first, the presence of a 5
the alternative pathway for mRNA decay in yeast proceeds to 3 exoribonuclease decay activity; second, the dem-
through 3 to 5decay mediated by the exosome complex, onstration that 3 to 5 exoribonucleolytic decay is the
we reasoned a DcpS activity should also be present in major contributor to mRNA decay; and third, the presence
yeast. A 32P-labeled cap analog (m7G*pppG) generated of a degradation-dependent decapping pathway where a
by nuclease P1 digestion of cap-labeled RNA (as in Figure subset of exosome proteins are associated with DcpS.
3C, lane 7) was used as the substrate with yeast extract. Eukaryotes contain at least two distinct decapping
The choice of this substrate was to distinguish between activities. The first is Dcp1p, which hydrolyzes a capped
the DcpS activity that functions on cap analog and the RNA to release m7GDP in yeast (Beelman et al., 1996;
well-characterized Dcp1p activity that does not hydrolyze LaGrandeur and Parker, 1998). The second activity is
this substrate. As shown in Figure 5, yeast extract contains the scavenger decapping activity reported in this study,
a DcpS activity that releases m7GMP (lane 2). As expected, which releases m7GMP, is present in both mammals
the activity is sensitive to m7GpppG competitor but not and yeast, and functions on the residual cap following
to GpppG competitor (lanes 3 and 4). The yeast DcpS degradation of the mRNA body. We believe the two
activity is distinct from Dcp1p and Dcp2p, since strains decapping activities involve distinct proteins. First,
containing a deletion of either gene encoding these pro- Dcp1p and Dcp1p-like activities are resistant to cap
teins possess DcpS activity (lanes 5 and 8). The pres- analog competition (LaGrandeur and Parker, 1998),
ence of DcpS in yeast suggests that this activity is con- while the DcpS activity is efficiently inhibited by cap
served from yeast to mammals. analog (Figure 3). Second, yeast strains lacking either
Dcp1p or Dcp2p still contain DcpS activity (Figure 5).
Third, in a parallel effort, we have cloned a gene encod-The Scavenger Decapping Activity Is Associated
with a Subset of Exosome Proteins ing a human Dcp1-like decapping activity, which func-
tions on capped RNA releasing m7GDP but does notGel filtration was used to begin a biochemical analysis
of the decapping activity. K562 S130 extract was re- function on a cap analog (Z.W., X. Jiao, and M.K., unpub-
lished data). Lastly, we more recently purified andsolved by a Superose 6 gel filtration column. To directly
detect the DcpS activity, labeled cap analog was used cloned a human cDNA encoding a 40 kDa protein that
possesses DcpS-like activity and hydrolyzes a cap ana-as the substrate. As shown in the top panel of Figure
6A, DcpS activity elutes with a peak centered at fractions log to release m7GMP (H. Liu, N. Rodgers, and M.K.,
unpublished data). The putative DcpS sequence was63 and 64 in the 80–90 kDa size range. Unlabeled
m7GpppG competitor was included in these reactions present in the database (GenBank accession number
AF077201) and was originally obtained by sequencingto slow the decapping and enable detection of the most
prominent peak. Otherwise, a broad peak extending to novel cDNAs isolated from human CD34 hematopoietic
stem/progenitor cells (HSPC015; Zhang et al., 2000).the 300 kDa range was detected (data not shown), sug-
gesting that DcpS could also be in larger complexes. This putative DcpS protein does not contain any recog-
nizable motifs or domains and is not homologous to anyInterestingly, when the same fractions were tested with
cap-labeled pcP RNA rather than the cap structure, the other human protein in the database. Collectively, these
Cell
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Figure 6. DcpS Can Exist in a 300 kDa Complex
(A) K562 S130 extract was fractionated on Superose 6, and aliquots from the indicated fractions were tested by an in vitro decay assay. The
substrate used in the top image was 32P-labeled cap analog (m7G*pppG) to detect the DcpS activity directly, independent of prior exoribonucleo-
lytic requirement. Cap-labeled pcP RNA was used as the substrate in the bottom image. The decapped products were resolved by TLC. The
DcpS activity is detected at approximately 80 kDa when labeled cap analog is used and at approximately 300 kDa with cap-labeled RNA,
suggesting that DcpS is associated with exoribonucleases in the larger complex. A schematic of the substrates is shown on the right, the
position of the molecular weight standards is shown at the top, and the standards are represented on the left. The positions of the DcpS
complex and free DcpS are indicated on the bottom.
(B) DcpS activity coimmunopurified with antisera to hRrp40p (hRrp40p) and hRrp41p (hRrp41p) from K562 S130 extract or extract pretreated
with micrococcal nuclease (RNase) using 32P-labeled cap analog as substrate. The respective control preimmune sera coimmunopurifications
are shown in lanes 6 and 7.
data support the presence of at least two distinct decap- dimerization of the 40 kDa putative DcpS protein. The
originally described activity was proposed to be a scav-ping proteins in eukaryotes.
Interestingly, a decapping activity similar to DcpS was enger for capped oligonucleotide byproducts of 3 to
5 exoribonuclease degradation (Furuichi and Shatkin,initially identified over 25 years ago by Shatkin and col-
leagues (Nuss et al., 1975). The activity hydrolyzed 1989). Our data confirms the original hypothesis and
demonstrates that DcpS can be associated within acapped oligonucleotides that were less than 10 nucleo-
tides long but did not decap longer mRNAs (Nuss and 300 kDa complex that includes a subset of the 3 to 5
exonuclease proteins contained within the exosome.Furuichi, 1977; Nuss et al., 1975). The 80 kDa size of
DcpS activity by gel filtration (Figure 6A) is consistent A prominent role has been attributed to 5 to 3 exori-
bonuclease activity in yeast, where the major pathwaywith the size of the activity described by Nuss and Furu-
ichi (1977), suggesting that both activities are the same. involves deadenylation-dependent decapping followed
by 5 to 3 exoribonuclease decay by the Xrn1 proteinHowever, we anticipate that the 80 kDa size results from
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nucleotide following decay. DcpS contains a pyrophos-
phatase activity that decaps the 5 end and releases
m7GMP. This model is particularly appealing because it
provides one large complex that mediates degradation
of the mRNA body and the hydrolysis of the 5 cap to
complete the demise of the mRNA. The presence of a
DcpS activity in yeast (Figure 5) suggests that a func-
tional link also exists between the yeast exosome pro-
teins and DcpS. Curiously, yeast DcpS had not pre-
viously been reported. Perhaps this is because the
substrate for DcpS results from the 3 to 5 decay pro-
cess, which is a minor contributor to mRNA turnover in
this organism.
Two additional pathways also exist in mammals,
which have not been listed in Figure 7. The first involves
deadenylation-dependent decapping of RNAs (Couttet
et al., 1997). Our data suggests that this pathway is a
minor contributor to mammalian mRNA decay. Consis-
tent with this premise, Couttet et al. (1997) estimated
that only 3% of deadenylated mRNAs were detected
to be decapped by an mRNA circularization, RT-PCR
assay. It is possible that this is a regulatory pathwayFigure 7. One Potential Pathway of mRNA Decay in Mammalian Cells
that is more extensively utilized under specific cellularAn mRNA with an interaction between the 5 and 3 termini is shown
conditions. A second pathway (also not represented inbetween the cap and poly(A) tail. Upon deadenylation, the major
pathway involves 3 to 5 exoribonucleolytic degradation of the RNA the model) involves the initiation of degradation by
by a complex consisting of DcpS and a subset of the exosome endoribonucleases (Schoenberg and Chernokalskaya,
proteins. After degradation of the mRNA body, the resulting cap is 1997). Endoribonuclease cleavage can be independent
hydrolyzed by DcpS. of the poly(A) tail and cleave the mRNA while it is still
polyadenylated (Binder et al., 1994; Brown et al., 1993;
Stoeckle and Hanafusa, 1989) or are inhibited by the(Beelman et al., 1996; Decker and Parker, 1994; LaGran-
poly(A) tail and cleave after deadenylation (Wang anddeur and Parker, 1998; Larimer et al., 1992; Muhlrad
Kiledjian, 2000a).et al., 1995). An alternative pathway involving 3 to 5
The yeast 3 to 5 exoribonuclease exosome complexexoribonuclease decay has also been demonstrated
consists of 11 proteins within a 485 kDa complex as(Anderson and Parker, 1998). Despite the cloning of a
determined by the calculated molecular weights of themouse homolog of XRN1, (Bashkirov et al., 1997), a
individual components (Allmang et al., 1999; Mitchell et
functional role for a 5 to 3 exoribonuclease activity has
al., 1997). Ten of these proteins are present in both
not previously been shown in mammalian mRNA decay.
the nucleus and cytoplasm while one, Rrp6p, is strictly
As shown in Figure 1, 5 to 3 exoribonuclease activity
nuclear. Similarly in humans, an exosome complex con-
is functional in mammalian extract. However, the relative sisting of 11–16 proteins has been identified (Allmang
lower contribution of this activity in the decay of RNA et al., 1999; Gelpi et al., 1990; Reimer et al., 1986) where
both in cytosolic extract and in cells (Figures 1 and 2) the Rrp6p homolog, PM/Scl 100, is restricted to the
suggests that degradation from the 5 end is not a major nucleus (Allmang et al., 1999). The association of DcpS
contributor to overall mRNA decay. with the hRrp40p and hRrp41p exosome proteins in a
The relative contributions of the two terminal exoribo- 300 kDa complex indicates that distinct subcomplexes
nucleases in mammalian mRNA decay appears to be of the exosome might exist. This is further supported
opposite of that in yeast. We propose that a major path- by a broad distribution in the 250–700 kDa size range
way (perhaps the default pathway) is deadenylation fol- for the hRrp40p, hRrp41p, and hRrp46p (Brouwer et al.,
lowed by 3 to 5 degradation-dependent decapping, 2001) and the exclusion of PM/Scl-100 (Rrp6p) from the
while an alternative pathway (possibly the regulatory cytoplasmic exosome complex (Allmang et al., 1999;
pathway) involves deadenylation-dependent direct de- Brouwer et al., 2001). It is plausible that the functional
capping. A model for the 3 to 5 mRNA degradation mRNA-specific exosome subcomplex in the cytoplasm
pathway is presented in Figure 7. Similar to yeast, the is 300 kDa and includes DcpS. However, it should be
initial step in mammalian mRNA turnover involves dead- noted that the extract used in our experiments is a post-
enylation. This is supported by both in vivo data (Shyu polysomal cytosolic extract. We cannot exclude the
et al., 1991; Wilson and Treisman, 1988) and in vitro data presence of another distinct complex(es) in the polyso-
(Bernstein et al., 1989; Brewer, 1998; Ford et al., 1999; mal fraction.
Wang et al., 1999). Following deadenylation, the promi- Proteins that associate with and possibly regulate the
nent contribution of the 3 to 5 exoribonucleases (Fig- specificity of the exosome have been reported. In yeast,
ures 1 and 2) suggests that degradation of the mRNA the DEVH box protein Ski2p has been proposed to be
from this direction is the more predominant pathway. a modulator of the exosome in mediating the specific
The coimmunopurification of a subset of the exosome decay of mRNA (Anderson and Parker, 1998). A second
proteins with DcpS implies that DcpS is associated with DEVH protein, Dob1p, was proposed to fulfill an analo-
gous modulatory role on the exosome components in-exoribonucleases and is presented to the capped oligo-
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(Amersham/Pharmacia). The column was equilibrated with 20 mMvolved in 5.8S pre-rRNA processing (de la Cruz et al.,
HEPES (pH 7.4) and 150 mM KCl. Collected were 250 l fractions,1998). The cap specificity of DcpS and the association of
and 20 l from each fraction was assayed for decapping activity inthis protein with the exosome makes DcpS an attractive
IVDA buffer. One micromolar unlabeled cap analog was included in
candidate as a regulator of the exosome complex re- the reactions presented on the top panel of Figure 6A to slow the
sponsible for mRNA decay. Further characterization of decapping reaction.
the putative DcpS protein will begin addressing this is-
Immunoprecipitationsue as well as how DcpS is regulated.
Immunoprecipitations were carried out with 10 l of either specific
antisera or preimmune sera bound to 20 l protein A beads. K562Experimental Procedures
S130 extract (300 g) was incubated with the antibody-coupled
beads at 4C for 2 hr in PBS containing 0.5% Triton X-100. UnboundRNA Production
proteins were removed with five washes of the same buffer and twoThe pcDNA3 polylinker (pcP) RNA was transcribed by T7 RNA poly-
washes with IVDA buffer. Where indicated, the extract was initiallymerase from a PCR-generated template using the T7 and SP6 pro-
treated with micrococcal nuclease (400 units/ml) at 37C for 20 min.moter primers. RNAs containing 60 adenosines or 16 guanosines
The presence of DcpS activity was determined by using 32P-labeledat the 3 end of the template were generated with a 3 SP6 promoter
cap analog generated by Nuclease P1. The labeled cap analog wasprimer containing 60 thymidines or 16 cytosines, respectively. RNAs
incubated with the immunopurified protein complex bound to thecontaining an internal G16 track were similarly generated from PCR
beads in IVDA buffer at 37C for 20 min. The product was extractedtemplates that used primers to insert 16 guanosines at nucleotide
once with phenol:chloroform (1:1) and twice with chloroform, and96 of pcP. Uniformly labeled and capped RNAs were transcribed in
the supernatant was resolved by TLC.vitro with T7 RNA polymerase in the presence of [-32P]UTP and
m7GpppG cap analog according to the manufacturer (Promega).
ElectroporationUniformly labeled and uncapped RNAs were similarly generated except
Uniformly labeled RNA (2  107 cpm/0.5 g) was electroporatedthat the m7GpppG cap analog was omitted. In vitro transcribed, unla-
into 107 K562 cells in a total volume of 400 l PBS in a 4 mm gapbeled, uncapped RNAs were cap labeled at the -phosphate (rela-
cuvette using a BioRad Genepulser charged at 320V, 500F. Alltive to the terminal guanine; m7G*pppG-) using the vaccinia virus
reagents were kept on ice prior to electroporation. Following dis-capping enzyme (Shuman, 1990) with [-32P]GTP and S-adenosyl-
charge, the cells were washed twice with PBS at room temperature,methionine (SAM), as described (Wang et al., 1999). All RNAs were
resuspended in prewarmed complete media, and placed at 37C.gel purified prior to use as described (Wang et al., 1999).
Cells were harvested at the indicated times, washed twice in PBS,
and lysed by vortexing in 300 l lysis buffer (10 mM Tris [pH 7.4],Extract Preparation
100 mM NaCl, 2.5 mM MgCl2, and 0.5% Triton X-100), which wasHuman erythroleukemia K562 cells and HeLa cells were obtained
spiked with a 32P-labeled oligonucleotide as an internal control forfrom Cellex Biosciences (Minneapolis, MN), and cytosolic S130 ex-
RNA precipitation and gel loading. The supernatant was extractedtract was prepared as described previously (Kiledjian et al., 1999).
once with an equal mixture of phenol and chloroform and the RNAPABP-depleted extract was generated by repeated incubations with
was ethanol precipitated and resolved on a 7 M urea/8% polyacryl-poly(A) Sepharose beads, as described (Wang et al., 1999). Yeast
amide denaturing gel.total extract was prepared according to Zhang et al. (1999b).
RNase Protection AssaysIn Vitro RNA Decay Assays
RNase protection assays were carried out as previously describedIn vitro mRNA decay assays were carried out at 37C with 50 g of
(Wang and Kiledjian, 2000a), using an antisense RNA to nucleotidesS130 extract for the indicated times in IVDA buffer (10 mM Tris [pH
249–350 (5 end) and to nucleotides 1829–2032 (3 end) of the c-myc7.5], 100 mM potassium acetate, 2 mM magnesium acetate, 2 mM
mRNA. The RNA were transcribed in the presence of [-32P]UTPDTT, 10 mM creatine phosphate, 1 mM ATP, 0.4 mM GTP, and 0.1
from a PCR-generated template that inserted a T7 polymerase pro-mM Spermine), as previously described (Wang et al., 1999). Where
moter on the 5 end and 35 nucleotide uncomplementary sequenceindicated, a 1 phosphatase inhibitor cocktail (Phosphatase inhibi-
on the 3 end.tor cocktail 1 and 2; Sigma) was included in the decay reactions.
Phosphatase treatment of the in vitro decay products was carried
Acknowledgmentsout with 10 units of calf intestinal alkaline phosphatase for 30 min
as recommended by the manufacturer (NEB). For the NDPK reaction,
We are indebted to H. Liu for providing unpublished results regard-the products of an in vitro decay reaction were phenol:chloroform
ing the DcpS protein. We thank G.J.M. Pruijn and R. Raijmakers for(1:1) extracted once and chloroform extracted twice and subse-
the exosome antisera, C.J. Wilusz and S. Peltz for the Dcp1 protein,quently treated with 1 unit NDPK (Sigma) for 30 min in the presence
and R. Parker for the yeast strains. We also thank N.D. Rodgers, A.of 1 mM ATP. Decapping reactions using Dcp1p were carried out
Shatkin, P. Trifillis, Y. Wen, G.J.M. Pruijn, R. Raijmakers, R. Parker,with 0.4 g protein and 0.1 pmol cap-labeled RNA, as described in
and C. Martin for helpful discussions and/or critical reading of theZhang et al. (1999b),
manuscript.
This work was supported by funds from the National Institutes ofDetection of Decapping Products
Health, grant DK51611 to M.K.In vitro decay reactions were stopped and extracted once with an
equal mixture of phenol:chloroform and twice with chloroform. An
Received June 20, 2001; revised November 2, 2001.aliquot was spotted onto PEI-cellulose TLC plates (Sigma) that were
prerun in H20 and air dried prior to use and the products developed
Referenceswith 0.45 M (NH4)2SO4 in a TLC chamber. The TLC plates were
dried and exposed to Kodak BioMax film. Radiolabeled inorganic
Allmang, C., Petfalski, E., Podtelejnikov, A., Mann, M., Tollervey, D.,phosphate in Figure 3 was generated by treating a 32P-end-labeled
and Mitchell, P. (1999). The yeast exosome and human PM-Scl areDNA oligonucleotide with calf intestinal phosphatase. All quantita-
related complexes of 3 → 5 exonucleases. Genes Dev. 13, 2148–tions were conducted with a Molecular Dynamics Phosphoroimager
2158.(Storm860) using ImageQuant-5 software. Nuclease P1 (Roche)
Anderson, J.S.J., and Parker, R.P. (1998). The 3 to 5 degradationtreatment of cap-labeled RNA was carried out with 1 unit enzyme
of yeast mRNAs is a general mechanism for mRNA turnover thatin 10 mM Tris (pH 7.5) and 1 mM ZnCl2 for 1 hr at 37C.
requires the SKI2 DEVH box protein and 3 to 5 exonucleases of
the exosome complex. EMBO J. 17, 1497–1506.Gel Filtration Chromatography
Gel filtration chromatography was carried out with 50 l of K562 Bashkirov, V.I., Scherthan, H., Solinger, J.A., Buerstedde, J.M., and
Heyer, W.D. (1997). A mouse cytoplasmic exoribonucleaseS130 extract (350 g protein) on a Superose-6 gel filtration column
Mammalian Degradation-Dependent Decapping
761
(mXRN1p) with preference for G4 tetraplex substrates. J. Cell Biol. Gingras, A.C., Raught, B., and Sonenberg, N. (1999). eIF4 initiation
factors: effectors of mRNA recruitment to ribosomes and regulators136, 761–773.
of translation. Annu. Rev. Biochem. 68, 913–963.Beelman, C.A., Stevens, A., Caponigro, G., LaGrandeur, T.E., Hat-
field, L., Fortner, D.M., and Parker, R. (1996). An essential component Green, M.R., Maniatis, T., and Melton, D.A. (1983). Human beta-
globin pre-mRNA synthesized in vitro is accurately spliced in Xeno-of the decapping enzyme required for normal rates of mRNA turn-
over. Nature 382, 642–646. pus oocyte nuclei. Cell 32, 681–694.
Hentze, M.W. (1997). eIF4G: a multipurpose ribosome adapter? Sci-Bernstein, P., Peltz, S.W., and Ross, J. (1989). The poly(A)-poly(A)-
binding protein complex is a major determinant of mRNA stability ence 275, 500–501.
in vitro. Mol. Cell. Biol. 9, 659–670. Hsu, C.L., and Stevens, A. (1993). Yeast cells lacking 5→3 exoribo-
nuclease 1 contain mRNA species that are poly(A) deficient andBinder, R., Horowitz, J.A., Basilion, J.P., Koeller, D.M., Klausner,
R.D., and Harford, J.B. (1994). Evidence that the pathway of trans- partially lack the 5 cap structure. Mol. Cell. Biol. 13, 4826–4835.
ferrin receptor mRNA degradation involves an endonucleolytic Izaurralde, E., Lewis, J., McGuigan, C., Jankowska, M., Darzynkie-
cleavage within the 3UTR and does not involve poly(A) tail shorten- wicz, E., and Mattaj, I.W. (1994). A nuclear cap binding protein com-
ing. EMBO J. 13, 1969–1980. plex involved in pre-mRNA splicing. Cell 78, 657–668.
Bonnerot, C., Boeck, R., and Lapeyre, B. (2000). The two proteins Izaurralde, E., Lewis, J., Gamberi, C., Jarmolowski, A., McGuigan,
Pat1p (Mrt1p) and Spb8p interact in vivo, are required for mRNA C., and Mattaj, I.W. (1995). A cap-binding protein complex mediating
decay, and are functionally linked to Pab1p. Mol. Cell. Biol. 20, U snRNA export. Nature 376, 709–712.
5939–5946.
Jarmolowski, A., Boelens, W.C., Izaurralde, E., and Mattaj, I.W.
Bousquet-Antonelli, C., Presutti, C., and Tollervey, D. (2000). Identifi- (1994). Nuclear export of different classes of RNA is mediated by
cation of a regulated pathway for nuclear pre-mRNA turnover. Cell specific factors. J. Cell Biol. 124, 627–635.
102, 765–775.
Kiledjian, M., Day, N., and Trifillis, P. (1999). Purification and RNA
Bouveret, E., Rigaut, G., Shevchenko, A., Wilm, M., and Seraphin, binding properties of the polycytidylate-binding proteins alphaCP1
B. (2000). A Sm-like protein complex that participates in mRNA and alphaCP2. Methods 17, 84–91.
degradation. EMBO J 19, 1661–1671.
Konarska, M.M., Padgett, R.A., and Sharp, P.A. (1984). Recognition
Brewer, G. (1998). Characterization of c-myc 3 to 5 mRNA decay of cap structure in splicing in vitro of mRNA precursors. Cell 38,
activities in an in vitro system. J. Biol. Chem. 273, 34770–34774. 731–736.
Brouwer, R., Allmang, C., Raijmakers, R., van Aarssen, Y., Egberts, Krieg, P.A., and Melton, D.A. (1984). Functional messenger RNAs
W.V., Petfalski, E., van Venrooij, W.J., Tollervey, D., and Pruijn, G.J. are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic
(2001). Three novel components of the human exosome. J. Biol. Acids Res. 12, 7057–7070.
Chem. 276, 6177–6184.
LaGrandeur, T.E., and Parker, R. (1998). Isolation and characteriza-
Brown, B.D., Zipkin, I.D., and Harland, R.M. (1993). Sequence-spe- tion of Dcp1p, the yeast mRNA decapping enzyme. EMBO J. 17,
cific endonucleolytic cleavage and protection of mRNA in Xenopus 1487–1496.
and Drosophila. Genes Dev. 7, 1620–1631.
Larimer, F.W., Hsu, C.L., Maupin, M.K., and Stevens, A. (1992). Char-
Couttet, P., Fromont-Racine, M., Steel, D., Pictet, R., and Grange, acterization of the XRN1 gene encoding a 5→3 exoribonuclease:
T. (1997). Messenger RNA deadenylylation precedes decapping in sequence data and analysis of disparate protein and mRNA levels
mammalian cells. Proc. Natl. Acad. Sci. USA 94, 5628–5633. of gene-disrupted yeast cells. Gene 120, 51–57.
de la Cruz, J., Kressler, D., Tollervey, D., and Linder, P. (1998). Dob1p Mitchell, P., Petfalski, E., Shevchenko, A., Mann, M., and Tollervey,
(Mtr4p) is a putative ATP-dependent RNA helicase required for the D. (1997). The exosome: a conserved eukaryotic RNA processing
3 end formation of 5.8S rRNA in Saccharomyces cerevisiae. EMBO complex containing multiple 3→5 exoribonucleases. Cell 91,
J. 17, 1128–1140. 457–466.
Decker, C.J., and Parker, R. (1993). A turnover pathway for both Muhlrad, D., Decker, C.J., and Parker, R. (1994). Deadenylation of
stable and unstable mRNAs in yeast: evidence for a requirement the unstable mRNA encoded by the yeast MFA2 gene leads to
for deadenylation. Genes Dev. 7, 1632–1643. decapping followed by 5→3 digestion of the transcript. Genes Dev.
8, 855–866.Decker, C.J., and Parker, R. (1994). Mechanisms of mRNA degrada-
tion in eukaryotes. Trends Biochem. Sci. 19, 336–340. Muhlrad, D., Decker, C.J., and Parker, R. (1995). Turnover mecha-
nisms of the stable yeast PGK1 mRNA. Mol. Cell. Biol. 15, 2145–Drummond, D.R., Armstrong, J., and Colman, A. (1985). The effect
of capping and polyadenylation on the stability, movement and 2156.
translation of synthetic messenger RNAs in Xenopus oocytes. Nu- Nuss, D.L., and Furuichi, Y. (1977). Characterization of the
cleic Acids Res. 13, 7375–7394. m7G(5)pppN-pyrophosphatase activity from HeLa cells. J. Biol.
Chem. 252, 2815–2821.Dunckley, T., and Parker, R. (1999). The DCP2 protein is required
for mRNA decapping in Saccharomyces cerevisiae and contains a Nuss, D.L., Furuichi, Y., Koch, G., and Shatkin, A.J. (1975). Detection
functional MutT motif. EMBO J. 18, 5411–5422. in HeLa cell extracts of a 7-methyl guanosine specific enzyme activ-
ity that cleaves m7GpppNm. Cell 6, 21–27.Ford, L.P., Watson, J., Keene, J.D., and Wilusz, J. (1999). ELAV
proteins stabilize deadenylated intermediates in a novel in vitro Reimer, G., Scheer, U., Peters, J.M., and Tan, E.M. (1986). Immunolo-
mRNA deadenylation/degradation system. Genes Dev. 13, 188–201. calization and partial characterization of a nucleolar autoantigen
(PM-Scl) associated with polymyositis/scleroderma overlap syn-Furuichi, Y., and Shatkin, A.J. (1989). Characterization of cap struc-
tures. Methods Enzymol. 180, 164–176. dromes. J. Immunol. 137, 3802–3808.
Ross, J. (1995). mRNA stability in mammalian cells. Microbiol. Rev.Furuichi, Y., and Shatkin, A.J. (2000). Viral and cellular mRNA cap-
ping: past and prospects. Adv. Virus Res. 55, 135–184. 59, 423–450.
Sachs, A.B. (1993). Messenger RNA degradation in eukaryotes. CellFuruichi, Y., LaFiandra, A., and Shatkin, A.J. (1977). 5-terminal struc-
ture and mRNA stability. Nature 266, 235–239. 74, 413–421.
Sachs, A.B., Sarnow, P., and Hentze, M.W. (1997). Starting at theGao, M., Wilusz, C.J., Peltz, S.W., and Wilusz, J. (2001). A novel
mRNA-decapping activity in HeLa cytoplasmic extracts is regulated beginning, middle, and end: translation initiation in eukaryotes. Cell
89, 831–838.by AU-rich elements. EMBO J. 20, 1134–1143.
Gelpi, C., Alguero, A., Angeles Martinez, M., Vidal, S., Juarez, C., Schoenberg, D.R., and Chernokalskaya, E. (1997). Ribonucleases
involved in eukaryotic mRNA turnover. In mRNA Metabolism andand Rodriguez-Sanchez, J.L. (1990). Identification of protein compo-
nents reactive with anti-PM/Scl autoantibodies. Clin. Exp. Immunol. Post-Transcriptional Gene Regulation, J.B. Harford and D.R. Morris,
eds. (New York: Wiley-Liss, Inc.), pp. 217–240.81, 59–64.
Cell
762
Shatkin, A.J. (1976). Capping of eucaryotic mRNAs. Cell 9, 645–653.
Shuman, S. (1990). Catalytic activity of vaccinia mRNA capping en-
zyme subunits coexpressed in Escherichia coli. J. Biol. Chem. 265,
11960–11966.
Shyu, A.B., Belasco, J.G., and Greenberg, M.E. (1991). Two distinct
destabilizing elements in the c-fos message trigger deadenylation
as a first step in rapid mRNA decay. Genes Dev. 5, 221–231.
Stoeckle, M.Y., and Hanafusa, H. (1989). Processing of 9E3 mRNA
and regulation of its stability in normal and Rous sarcoma virus-
transformed cells. Mol. Cell. Biol. 9, 4738–4745.
Wang, Z., and Kiledjian, M. (2000a). Identification of an erythroid-
enriched endoribonuclease activity involved in specific mRNA cleav-
age. EMBO J. 19, 295–305.
Wang, Z., and Kiledjian, M. (2000b). The poly(A)-binding protein
and an mRNA stability protein jointly regulate an endoribonuclease
activity. Mol. Cell. Biol. 20, 6334–6341.
Wang, Z., Day, N., Trifillis, P., and Kiledjian, M. (1999). An mRNA
stability complex functions with poly(A)-binding protein to stabilize
mRNA in vitro. Mol. Cell. Biol. 19, 4552–4560.
Wickens, M.P., and Gurdon, J.B. (1983). Post-transcriptional pro-
cessing of simian virus 40 late transcripts in injected frog oocytes.
J. Mol. Biol. 163, 1–26.
Wilson, T., and Treisman, R. (1988). Removal of poly(A) and conse-
quent degradation of c-fos mRNA facilitated by 3 AU-rich se-
quences. Nature 336, 396–399.
Zhang, S., Williams, C.J., Hagan, K., and Peltz, S.W. (1999a). Muta-
tions in VPS16 and MRT1 stabilize mRNAs by activating an inhibitor
of the decapping enzyme. Mol. Cell. Biol. 19, 7568–7576.
Zhang, S., Williams, C.J., Wormington, M., Stevens, A., and Peltz,
S.W. (1999b). Monitoring mRNA decapping activity. Methods 17,
46–51.
Zhang, Q.H., Ye, M., Wu, X.Y., Ren, S.X., Zhao, M., Zhao, C.J., Fu,
G., Shen, Y., Fan, H.Y., Lu, G., et al. (2000). Cloning and functional
analysis of cDNAs with open reading frames for 300 previously
undefined genes expressed in CD34 hematopoietic stem/progeni-
tor cells. Genome Res. 10, 1546–1560.
